{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:45:02Z","timestamp":1793108702628,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001636","name":"University College Cork","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001636","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The European Medicines Agency has recommended a series of restrictions on the use of sodium valproate (valproate) following research linking its exposure in utero to adverse congenital and neurodevelopmental effects in offspring. Recent research has highlighted a potential increased risk of neurodevelopmental disorders in children born to males taking valproate prior to conception. Clinicians and patients require guidance regarding suitable alternatives.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>To provide an overview of suitable alternatives to valproate in the management of bipolar disorder.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>A narrative review was conducted. Only medications with an established evidence base in managing different phases of bipolar disorder and endorsed within clinical practice guidelines were considered. Eligible guidelines included those (i) where recommendations were informed by a formal guideline development process and (ii) published in English within the last 15\u00a0years. REPROTOX\u00ae was chosen as the primary information source regarding reproductive safety of alternative medications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of all second-generation antipsychotics, quetiapine should be considered a first-line alternative to valproate. Lithium has been associated with an increased risk of cardiac malformations, especially Ebstein anomaly, following in utero exposure. However, given its robust efficacy as an antimanic agent and the absolute risk of cardiac abnormalities being low, it\u2019s use can still be considered in individuals of child-bearing potential with appropriate monitoring. Carbamazepine treatment should be avoided due to concerns for teratogenicity. Although considered safe in pregnancy, lamotrigine is largely effective at preventing relapse of bipolar depression. Thus, lamotrigine offers limited clinical utility as an alternative to valproate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Specific recommendations are made regarding alternatives to valproate in managing bipolar disorder.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11096-025-01919-x","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T10:31:34Z","timestamp":1745836294000},"page":"666-675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative efficacy and safety of alternatives to sodium valproate in the management of bipolar affective disorder in people of child-bearing age: a narrative review by the European Society of Clinical Pharmacy\u2019s mental health specialist interest group"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9570-8823","authenticated-orcid":false,"given":"Ita","family":"Fitzgerald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izgi","family":"Bayraktar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Eiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind","family":"Gittins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Magni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Humbert-Claude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara-Turiya","family":"Molitschnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Darm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Waksmundzka-Walczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Riesenhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matej","family":"Stuhec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Ta\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"1919_CR1","unstructured":"Valproate and related substances\u2014European Medicines Agency (2018) https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/valproate-related-substances-0. Accessed 24 July 2024."},{"key":"1919_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S1474-4422(24)00141-8","volume":"23","author":"F Rugg-Gunn","year":"2024","unstructured":"Rugg-Gunn F, Hunt D. The prescription of valproate: risk of harm. Lancet Neurol. 2024;23:557\u20138.","journal-title":"Lancet Neurol"},{"key":"1919_CR3","unstructured":"Valproate safety measures. GOV.UK (2024) https:\/\/www.gov.uk\/government\/collections\/valproate-safety-measures. Accessed 24 July 2024."},{"key":"1919_CR4","first-page":"CD004052.5","volume":"1","author":"K Macritchie","year":"2003","unstructured":"Macritchie K, Geddes JR, Scott J, et al. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev. 2003;1:CD004052.5.","journal-title":"Cochrane Database Syst Rev."},{"key":"1919_CR5","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41380-021-01334-4","volume":"27","author":"T Kishi","year":"2022","unstructured":"Kishi T, Ikuta T, Matsuda Y, et al. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Mol Psychiatry. 2022;27:1136\u201344.","journal-title":"Mol Psychiatry."},{"key":"1919_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham LN, Kennedy SH, Parikh SV, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97\u2013170. https:\/\/doi.org\/10.1111\/bdi.12609.","journal-title":"Bipolar Disord"},{"key":"1919_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bdi.13135","volume":"23","author":"LN Yatham","year":"2021","unstructured":"Yatham LN, Chakrabarty T, Bond DJ, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. Bipolar Disord. 2021;23:767\u201388. https:\/\/doi.org\/10.1111\/bdi.13135.","journal-title":"Bipolar Disord"},{"key":"1919_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/15622975.2017.1384850","volume":"19","author":"H Grunze","year":"2018","unstructured":"Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry. 2018;19:2\u201358. https:\/\/doi.org\/10.1080\/15622975.2017.1384850.","journal-title":"World J Biol Psychiatry."},{"key":"1919_CR9","unstructured":"Recommendations | Bipolar disorder: assessment and management. NICE (2014) https:\/\/www.nice.org.uk\/guidance\/cg185\/chapter\/1-Recommendations. Accessed 23 July 2024."},{"key":"1919_CR10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3109\/15622975.2013.770551","volume":"14","author":"H Grunze","year":"2013","unstructured":"Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14:154\u2013219. https:\/\/doi.org\/10.3109\/15622975.2013.770551.","journal-title":"World J Biol Psychiatry"},{"key":"1919_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3109\/15622970903555881","volume":"11","author":"H Grunze","year":"2010","unstructured":"Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11:81\u2013109.","journal-title":"World J Biol Psychiatry"},{"key":"1919_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/15622970902823202","volume":"10","author":"H Grunze","year":"2009","unstructured":"Grunze H, Vieta E, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry. 2009;10:85\u2013116. https:\/\/doi.org\/10.1080\/15622970902823202.","journal-title":"World J Biol Psychiatry."},{"key":"1919_CR13","unstructured":"Reprotox. https:\/\/reprotox.org\/. Accessed 5 Dec 2024."},{"issue":"8","key":"1919_CR14","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1038\/s41380-020-00946-6","volume":"26","author":"T Kishi","year":"2021","unstructured":"Kishi T, Ikuta T, Matsuda Y, et al. Mood stabilizers and\/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. Mol Psychiatry. 2021;26(8):4146\u201357. https:\/\/doi.org\/10.1038\/s41380-020-00946-6.","journal-title":"Mol Psychiatry"},{"key":"1919_CR15","unstructured":"Reprotox\u2014Aripiprazole. https:\/\/reprotox.org\/. Accessed 5 Dec 2024."},{"issue":"2","key":"1919_CR16","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41380-021-01334-4","volume":"27","author":"T Kishi","year":"2022","unstructured":"Kishi T, Ikuta T, Matsuda Y, et al. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Mol Psychiatry. 2022;27(2):1136\u201344. https:\/\/doi.org\/10.1038\/s41380-021-01334-4.","journal-title":"Mol Psychiatry"},{"key":"1919_CR17","unstructured":"Reprotox\u2014Carbamazepine. Available from: https:\/\/reprotox.org\/. Accessed 3 Dec 2024."},{"key":"1919_CR18","unstructured":"Reprotox\u2014Haloperidol. Available from: https:\/\/reprotox.org\/. Accessed 5 Dec 2024."},{"key":"1919_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.euroneuro.2021.10.003","volume":"54","author":"KN Fountoulakis","year":"2022","unstructured":"Fountoulakis KN, Tohen M, Zarate CA Jr. Lithium treatment of Bipolar disorder in adults: a systematic review of randomized trials and meta-analyses. Eur Neuropsychopharmacol. 2022;54:100\u201315. https:\/\/doi.org\/10.1016\/j.euroneuro.2021.10.003.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1919_CR20","unstructured":"Reprotox\u2014Lithium. Available from: https:\/\/reprotox.org\/. Accessed 3 Dec 2024."},{"key":"1919_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41380-024-02697-0","volume":"30","author":"N Fabiano","year":"2025","unstructured":"Fabiano N, Wong S, Gupta A, et al. Safety of psychotropic medications in pregnancy: an umbrella review. Mol Psychiatry. 2025;30:327\u201335. https:\/\/doi.org\/10.1038\/s41380-024-02697-0.","journal-title":"Mol Psychiatry"},{"key":"1919_CR22","unstructured":"https:\/\/www.cochrane.org\/CD013575\/DEPRESSN_lamotrigine-treatment-prevention-recurrence-bipolar-disorder conclusion"},{"key":"1919_CR23","unstructured":"Medicines.ie. Lamictal 100 mg tablets: Summary of Product Characteristics. Medicines.ie. 2024. https:\/\/www.medicines.ie\/medicines\/lamictal-100mg-tablets-32627\/spc"},{"issue":"9","key":"1919_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S2215-0366(23)00199-2","volume":"10","author":"A Yildiz","year":"2023","unstructured":"Yildiz A, Siafis S, Mavridis D, et al. Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2023;10(9):693\u2013705. https:\/\/doi.org\/10.1016\/S2215-0366(23)00199-2.","journal-title":"Lancet Psychiatry"},{"key":"1919_CR25","unstructured":"Reprotox\u2014Lamotrigine. Available from: https:\/\/reprotox.org\/. Accessed 1 Dec 2024"},{"key":"1919_CR26","unstructured":"Reprotox\u2014Olanzapine. Available from: https:\/\/reprotox.org\/. Accessed 4 Dec 2024."},{"key":"1919_CR27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/archgenpsychiatry.2011.1870","volume":"69","author":"R Bod\u00e9n","year":"2012","unstructured":"Bod\u00e9n R, Lundgren M, Brandt L, et al. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry. 2012;69:715\u201321. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2011.1870.","journal-title":"Arch Gen Psychiatry"},{"key":"1919_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101690","volume":"54","author":"TW Hsu","year":"2022","unstructured":"Hsu TW, Thompson T, Solmi M, et al. Variability and efficacy in treatment effects on manic symptoms with lithium, anticonvulsants, and antipsychotics in acute bipolar mania: a systematic review and meta-analysis. E Clin Med. 2022;54: 101690. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101690.","journal-title":"E Clin Med"},{"key":"1919_CR29","unstructured":"Reprotox\u2014Quetiapine. Available from: https:\/\/reprotox.org\/. Accessed 5 Dec 2024."},{"key":"1919_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40263-022-00908-2","volume":"36","author":"E Heinonen","year":"2022","unstructured":"Heinonen E, Forsberg L, N\u00f6rby U, et al. Antipsychotic use during pregnancy and risk for gestational diabetes: a national register-based cohort study in Sweden. CNS Drugs. 2022;36:529\u201339. https:\/\/doi.org\/10.1007\/s40263-022-00908-2.","journal-title":"CNS Drugs"},{"key":"1919_CR31","unstructured":"Reprotox\u2014Risperidone. Available from: https:\/\/reprotox.org\/. Accessed 5 Dec 2024."},{"key":"1919_CR32","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1176\/appi.ajp.2018.17040393","volume":"175","author":"Y Park","year":"2018","unstructured":"Park Y, Hernandez-Diaz S, Bateman BT, et al. Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. Am J Psychiatry. 2018;175:564\u201374. https:\/\/doi.org\/10.1176\/appi.ajp.2018.17040393.","journal-title":"Am J Psychiatry"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01919-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-01919-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01919-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:36:31Z","timestamp":1748586991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-01919-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1919"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-01919-x","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"26 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Matej Stuhec is an associate editor of the International Journal of Clinical Pharmacy. He had no role in handling the manuscript, specifically the processes of editorial review, peer review and decision making.\u00a0The remaining authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}